SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 15041517.
  • 2
    Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 14241429.
  • 3
    Sewell JL, Yee HF Jr, Inadomi JM. Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 204207.
  • 4
    Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol. 2004; 99: 650655.
    Direct Link:
  • 5
    Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008; 24: 319328.
  • 6
    Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. Occup Environ Med. 2008; 50: 12611272.
  • 7
    Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 19071913.
  • 8
    Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Disease. 2010 [Epub ahead of print].
  • 9
    Odes S, Vardi H, Friger M, et al. European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131: 719728.
  • 10
    Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000; 95: 677683.
    Direct Link:
  • 11
    Hillson E, Dybicz S, Waters HC, et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. Occup Environ Med. 2008; 50: 969977.
  • 12
    Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008; 14: 352362.
  • 13
    Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000; 95: 524530.
    Direct Link:
  • 14
    Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117: 4957.
  • 15
    Cohen RD, Waters HC, Tang B, et al. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008; 14: 17071714.
  • 16
    Levesque BG, Cipriano LE, Chang SL, et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8: 261267.
  • 17
    Goldfarb NI, Pizzi LT, Fuhr JP Jr, et al. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Dis Manag. 2004; 7: 292304.
  • 18
    Provenzale D, Wong JB, Onken JE, et al. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol. 1998; 93: 872880.
    Direct Link:
  • 19
    Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease. Ulcerative colitis. J Clin Gastroenterol. 2001; 32: 99105.
  • 20
    Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol. 2009; 104: 22222232.
  • 21
    Shen B, Shermock KM, Fazio VW, et al. A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2003; 98: 24602467.
  • 22
    Parsi MA, Ellis JJ, Lashner BA. Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol. 2008; 42: 799805.
  • 23
  • 24
    Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009; 54: 11571170.
  • 25
    Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface. 2006; 19: 3946,56.
  • 26
    Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 12871296.
  • 27
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005; 1: CD003715.
  • 28
    Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100: 22392247.
    Direct Link:
  • 29
    Waljee AK, Joyce JC, Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol. 2010; 8: 143150.
  • 30
    2006 Drug topics, red book. Montvale, NJ: Medical Economics; 2006.
  • 31
    Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006; 13: 502506.
  • 32
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 33
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 24622476.
  • 34
    Thomas T, Cohen RD. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007; 1: 101112.
  • 35
    Irving PM, Gibson PR. Infliximab: getting the most for your money. J Gastroenterol Hepatol. 2007; 22: 15591561.
  • 36
    Cohen RD, Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006; 35: 867882.
  • 37
    Jaisson-Hot I, Flourié B, Descos L, et al. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004; 20: 274279.
  • 38
    Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007; 26: 13131323.
  • 39
    Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008; 28: 7687.
  • 40
    Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 12301239.
  • 41
    Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology. 2001; 120: 16401656.
  • 42
    Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr Gastroenterol Nutr. 2005; 40: 6769.
  • 43
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 5265.
  • 44
    Wu EQ, Mulani PM, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008; 11: 820829.
  • 45
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492500.
  • 46
    Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 15091520.
  • 47
    Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics. 2009; 27: 609621.
  • 48
    Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009; 15: 581588.
  • 49
    Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009; 69: 12991310.
  • 50
    Swenson BR, Hollenbeak CS, Poritz LS, et al. Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization. Dis Colon Rectum. 2005; 48: 256261.
  • 51
    Holubar SD, Long KH, Loftus EV Jr, et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum. 2009; 52: 18151823.
  • 52
    Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009; 29: 247257.
  • 53
    Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53: 10201024.
  • 54
    Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003; 98: 10641072.
  • 55
    Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99: 9196.
    Direct Link:
  • 56
    Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol. 2003; 98: 844849.
    Direct Link: